Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
Huan Yu, Vincent C Woo Department of Medicine, Division of Endocrinology and Metabolism, Health Sciences Centre, University of Manitoba, Winnipeg, MB, Canada Aims: The aim of this article is to review the safety and efficacy data of dapagliflozin, saxagliptin, and their combination in the m...
Enregistré dans:
Auteurs principaux: | Yu H, Woo VC |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/dbb34e9ada984dba808d4585df353ff7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
par: Kuecker CM, et autres
Publié: (2016) -
Saxagliptin for type 2 diabetes
par: Chacra
Publié: (2010) -
New prospects in the treatment of diabetes mellitus
par: Minara Shamkhalovna Shamkhalova, et autres
Publié: (2012) -
Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
par: Kawarasaki S, et autres
Publié: (2020) -
A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
par: Shen L, et autres
Publié: (2021)